Quick Answer
Crinetics Pharmaceuticals, Inc. reported Stockholders Equity of $992.08 million for the year ending 2025.
- Crinetics Pharmaceuticals, Inc. showed a decrease of -25.1% in Stockholders Equity from 2024 to 2025.
- This data is from Crinetics Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$19.98 million | Q2 2018: -$25.18 million | Q3 2018: $167.52 million | Q1 2019: $152.39 million | Q2 2019: $142.10 million | Q3 2019: $129.52 million | Q1 2020: $108.44 million | Q2 2020: $202.77 million | Q3 2020: $187.22 million | Q1 2021: $149.48 million | Q2 2021: $201.44 million | Q3 2021: $193.59 million | Q1 2022: $303.04 million | Q2 2022: $386.17 million | Q3 2022: $351.37 million | Q1 2023: $280.33 million | Q2 2023: $254.12 million | Q3 2023: $547.75 million | Q1 2024: $874.93 million | Q2 2024: $830.76 million | Q3 2024: $832.98 million | Q1 2025: $1.25 billion | Q2 2025: $1.17 billion | Q3 2025: $1.07 billion.
- Over the full 11 years of available data (2015 to 2025), Crinetics Pharmaceuticals, Inc.'s Stockholders Equity has grown by 214,372.8%.
- Historical annual values: Fiscal year 2025: $992.08 million | Fiscal year 2024: $1.32 billion | Fiscal year 2023: $539.11 million | Fiscal year 2022: $316.33 million | Fiscal year 2021: $331.94 million | Fiscal year 2020: $168.92 million | Fiscal year 2019: $117.14 million | Fiscal year 2018: $160.23 million | Fiscal year 2017: -$15.02 million | Fiscal year 2016: -$6.20 million | Fiscal year 2015: -$463.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: